Capsaicin reduces blood glucose and prevents prostate growth by regulating androgen, RAGE/IGF-1/Akt, TGF-β/Smad signalling pathway and reversing epithelial-mesenchymal transition in streptozotocin-induced diabetic mice-Reference-Cited by-同舟云学术

Capsaicin reduces blood glucose and prevents prostate growth by regulating androgen, RAGE/IGF-1/Akt, TGF-β/Smad signalling pathway and reversing epithelial-mesenchymal transition in streptozotocin-induced diabetic mice

Published:2024-05-03 Issue: Volume: Page:
ISSN:0028-1298
Container-title:Naunyn-Schmiedeberg's Archives of Pharmacology
language:en
Short-container-title:Naunyn-Schmiedeberg's Arch Pharmacol

Author:

Sun Hui,Wang ZiTong,Tu BingHua,Shao ZiChen,Li YiDan,Han Di,Jiang YinJie,Zhang Peng,Zhang WeiChang,Wu YunYan,Wu XiaoMing,Liu Chi-Ming

Funder

Yichun University Local Development Research Center

PhD Research Foundation of Yichun University

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00210-024-03092-w.pdf

Reference78 articles.

1. Aghazadeh Tabrizi M, Baraldi PG, Baraldi S, Gessi S, Merighi S, Borea PA (2017) Medicinal chemistry, pharmacology, and clinical implications of TRPV1 receptor antagonists. Med Res Rev 37(4):936–983

2. Alonso-Magdalena P, Brossner C, Reiner A, Cheng G, Sugiyama N, Warner M, Gustafsson JA (2009) A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc Natl Acad Sci U S A 106(8):2859–2863

3. Assar ME, Angulo J, Rodriguez-Manas L (2016) Diabetes and ageing-induced vascular inflammation. J Physiol 594(8):2125–2146

4. Berger AP, Kofler K, Bektic J, Rogatsch H, Steiner H, Bartsch G, Klocker H (2003) Increased growth factor production in a human prostatic stromal cell culture model caused by hypoxia. Prostate 57(1):57–65

5. Berger AP, Deibl M, Halpern EJ, Lechleitner M, Bektic J, Horninger W, Fritsche G, Steiner H, Pelzer A, Bartsch G, Frauscher F (2005) Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia. Diabetologia 48(4):784–789